亚盛医药(06855.HK) 公布,其原创1类新药奥雷巴替尼(商品名:耐立克)获国家药监局(NMPA)药品审评中心(CDE)纳入“突破性治疗品种”名单,用于联合化疗一线治疗新诊断费城染色体阳性(Ph+)急性淋巴细胞白血病(ALL)患者。(jl/w)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-05 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.